IS IT POSSIBLE TO DIAGNOSE LOW RISK MYELODYSPLASTIC SYNDROME (MDS) BY FLOW CYTOMETRY?
(Abstract release date: 05/19/16)
EHA Library. Atilla E. 06/09/16; 132776; E1227
Dr. Erden Atilla
Contributions
Contributions
Abstract
Abstract: E1227
Type: Eposter Presentation
Background
World Health Organization (WHO) classifies myelodysplastic syndromes due to patolological hallmark of marrow dysplasia. Flow cytometry immunophenotyping has a crucial role in diagnosis and management of hematological malignancies. Ogata et al. demostrated a simple flow cytometry (FCM) score which helped to establish the diagnosis of MDS in patients without specific markers of marrow dysplasia.
Aims
Our aim in this study is to evaluate the patients who had biopsied for diagnosis of MDS in 2015, confirm with pathology and restage them with FCM-score at Ankara University School of Medicine Department of Hematology.
Methods
From 386 patients presented with cytopenias, 78 (20%) was morphologically diagnosed with MDS. Four parameters were combined in a regression model in FCM score; increased myeloblast-related cluster size, decreased B-progenitor related cluster size, aberrant CD45 expression and reduced granulocyte side scatter. All MDS diagnosed patients were reevaluated with FCM score. The diagnosis of MDS was formulated in the case that the value of the FCM-score was 2 or more. Chi-squared test was used for categorical variables.
Results
Median age of 78 patients was 62 (range, 18-90), 49 (62%) of them was male. Patient characteristics were shown in table. Totally 44 patients (56%) from 78 patients had FCM-score 2 or more. Patients with MDS without specific markers of marrow dysplasia (such as ring sideroblasts and/or clonal chromosomal abnormalities) were 34% of FCM score positive population. In MDS patients high FCM score (3 or 4) was found to be significantly associated with transfusion dependency (P=0.021) and resulting in higher WPSS risk (P=0.002).
Conclusion
FCM score can be a new tool for low risk MDS patients without specific markers of marrow dysplasia.
Session topic: E-poster
Keyword(s): Flow cytometry, Myelodysplasia
Type: Eposter Presentation
Background
World Health Organization (WHO) classifies myelodysplastic syndromes due to patolological hallmark of marrow dysplasia. Flow cytometry immunophenotyping has a crucial role in diagnosis and management of hematological malignancies. Ogata et al. demostrated a simple flow cytometry (FCM) score which helped to establish the diagnosis of MDS in patients without specific markers of marrow dysplasia.
Aims
Our aim in this study is to evaluate the patients who had biopsied for diagnosis of MDS in 2015, confirm with pathology and restage them with FCM-score at Ankara University School of Medicine Department of Hematology.
Methods
From 386 patients presented with cytopenias, 78 (20%) was morphologically diagnosed with MDS. Four parameters were combined in a regression model in FCM score; increased myeloblast-related cluster size, decreased B-progenitor related cluster size, aberrant CD45 expression and reduced granulocyte side scatter. All MDS diagnosed patients were reevaluated with FCM score. The diagnosis of MDS was formulated in the case that the value of the FCM-score was 2 or more. Chi-squared test was used for categorical variables.
Results
Median age of 78 patients was 62 (range, 18-90), 49 (62%) of them was male. Patient characteristics were shown in table. Totally 44 patients (56%) from 78 patients had FCM-score 2 or more. Patients with MDS without specific markers of marrow dysplasia (such as ring sideroblasts and/or clonal chromosomal abnormalities) were 34% of FCM score positive population. In MDS patients high FCM score (3 or 4) was found to be significantly associated with transfusion dependency (P=0.021) and resulting in higher WPSS risk (P=0.002).
Conclusion
FCM score can be a new tool for low risk MDS patients without specific markers of marrow dysplasia.
Session topic: E-poster
Keyword(s): Flow cytometry, Myelodysplasia
Abstract: E1227
Type: Eposter Presentation
Background
World Health Organization (WHO) classifies myelodysplastic syndromes due to patolological hallmark of marrow dysplasia. Flow cytometry immunophenotyping has a crucial role in diagnosis and management of hematological malignancies. Ogata et al. demostrated a simple flow cytometry (FCM) score which helped to establish the diagnosis of MDS in patients without specific markers of marrow dysplasia.
Aims
Our aim in this study is to evaluate the patients who had biopsied for diagnosis of MDS in 2015, confirm with pathology and restage them with FCM-score at Ankara University School of Medicine Department of Hematology.
Methods
From 386 patients presented with cytopenias, 78 (20%) was morphologically diagnosed with MDS. Four parameters were combined in a regression model in FCM score; increased myeloblast-related cluster size, decreased B-progenitor related cluster size, aberrant CD45 expression and reduced granulocyte side scatter. All MDS diagnosed patients were reevaluated with FCM score. The diagnosis of MDS was formulated in the case that the value of the FCM-score was 2 or more. Chi-squared test was used for categorical variables.
Results
Median age of 78 patients was 62 (range, 18-90), 49 (62%) of them was male. Patient characteristics were shown in table. Totally 44 patients (56%) from 78 patients had FCM-score 2 or more. Patients with MDS without specific markers of marrow dysplasia (such as ring sideroblasts and/or clonal chromosomal abnormalities) were 34% of FCM score positive population. In MDS patients high FCM score (3 or 4) was found to be significantly associated with transfusion dependency (P=0.021) and resulting in higher WPSS risk (P=0.002).
Conclusion
FCM score can be a new tool for low risk MDS patients without specific markers of marrow dysplasia.
Session topic: E-poster
Keyword(s): Flow cytometry, Myelodysplasia
Type: Eposter Presentation
Background
World Health Organization (WHO) classifies myelodysplastic syndromes due to patolological hallmark of marrow dysplasia. Flow cytometry immunophenotyping has a crucial role in diagnosis and management of hematological malignancies. Ogata et al. demostrated a simple flow cytometry (FCM) score which helped to establish the diagnosis of MDS in patients without specific markers of marrow dysplasia.
Aims
Our aim in this study is to evaluate the patients who had biopsied for diagnosis of MDS in 2015, confirm with pathology and restage them with FCM-score at Ankara University School of Medicine Department of Hematology.
Methods
From 386 patients presented with cytopenias, 78 (20%) was morphologically diagnosed with MDS. Four parameters were combined in a regression model in FCM score; increased myeloblast-related cluster size, decreased B-progenitor related cluster size, aberrant CD45 expression and reduced granulocyte side scatter. All MDS diagnosed patients were reevaluated with FCM score. The diagnosis of MDS was formulated in the case that the value of the FCM-score was 2 or more. Chi-squared test was used for categorical variables.
Results
Median age of 78 patients was 62 (range, 18-90), 49 (62%) of them was male. Patient characteristics were shown in table. Totally 44 patients (56%) from 78 patients had FCM-score 2 or more. Patients with MDS without specific markers of marrow dysplasia (such as ring sideroblasts and/or clonal chromosomal abnormalities) were 34% of FCM score positive population. In MDS patients high FCM score (3 or 4) was found to be significantly associated with transfusion dependency (P=0.021) and resulting in higher WPSS risk (P=0.002).
Conclusion
FCM score can be a new tool for low risk MDS patients without specific markers of marrow dysplasia.
Session topic: E-poster
Keyword(s): Flow cytometry, Myelodysplasia
{{ help_message }}
{{filter}}